Budesonide/formoterol fumarate dihydrate versus budesonide with a novel suspension technology for uncontrolled asthma: phase 3 VATHOS study.

PubMed 2026 Open access

Read full text
Authors: David J Jackson, Robert Wise, Alberto Papi, Njira Lugogo, Ruchong Chen, Hassan Chami, Clara Armengol, Sami Z. Daoud, Emma Nauclér, Karin Bowen, Ayman Megally, Olami Sobande
+1 more Mehul Patel
DOI: 10.1183/23120541.01817-2025
Cited by: 1
References: 23

Abstract

Background: ). Methods: , 5 min post-dose) and severe exacerbation rates (secondary). Adverse events (AEs) were recorded. Results: in lung function. Conclusion: 320 with co-suspension delivery technology in people with inadequately controlled asthma on medium-dose ICS or ICS/LABA.

Fields of Study & Subjects

Asthma and respiratory diseases Inhalation and Respiratory Drug Delivery Respiratory and Cough-Related Research

Publication details

Journal / source
PubMed
Publisher
European Respiratory Society (ERS)
Volume
12
Issue
5
Pages
01817-2025
Publication date
1 September 2026
Language
EN